Literature DB >> 23340477

Playing Russian roulette with tyrosine kinase inhibitors.

R Z Szmulewitz1, M J Ratain.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 23340477     DOI： 10.1038/clpt.2012.245

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  5 in total

1.  Targeted therapies: redefining the primary objective of phase I oncology trials.

Authors:  Mark J Ratain
Journal:  Nat Rev Clin Oncol       Date:  2014-08-05       Impact factor: 66.675

Review 2.  Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.

Authors:  Huixin Yu; Neeltje Steeghs; Cynthia M Nijenhuis; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Journal:  Clin Pharmacokinet       Date:  2014-04       Impact factor: 6.447

Review 3.  Determining the optimal dose in the development of anticancer agents.

Authors:  Ron H J Mathijssen; Alex Sparreboom; Jaap Verweij
Journal:  Nat Rev Clin Oncol       Date:  2014-03-25       Impact factor: 66.675

4.  Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.

Authors:  Russell Z Szmulewitz; Cody J Peer; Abiola Ibraheem; Elia Martinez; Mark F Kozloff; Bradley Carthon; R Donald Harvey; Paul Fishkin; Wei Peng Yong; Edmund Chiong; Chadi Nabhan; Theodore Karrison; William D Figg; Walter M Stadler; Mark J Ratain
Journal:  J Clin Oncol       Date:  2018-03-28       Impact factor: 50.717

5.  Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520.

Authors:  Remy B Verheijen; Diane A J van der Biessen; Sebastien J Hotte; Lillian L Siu; Anna Spreafico; Maja J A de Jonge; Linda C Pronk; Filip Y F L De Vos; David Schnell; Hal W Hirte; Neeltje Steeghs; Martijn P Lolkema
Journal:  Target Oncol       Date:  2019-02       Impact factor: 4.493
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.